{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:21:20Z","timestamp":1783948880403,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,7]]},"DOI":"10.7759\/cureus.15507","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T22:27:39Z","timestamp":1623104859000},"source":"Crossref","is-referenced-by-count":1,"title":["Renal Phosphate Wasting Due to Tumor-Induced (Oncogenic) Osteomalacia"],"prefix":"10.7759","author":[{"given":"Eluwana A","family":"Amaratunga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily B","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kamau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragarupa","family":"Kotala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-012-2175-z","article-title":"Phosphate homeostasis and its role in bone health","volume":"27","author":"Goretti Penido M","year":"2012","unstructured":"Goretti Penido M, Alon US. Phosphate homeostasis and its role in bone health. Pediatr Nephrol. 2012, 27:2039-2048. 10.1007\/s00467-012-2175-z","journal-title":"Pediatr Nephrol"},{"key":"ref2","article-title":"Osteomalacia","author":"Zimmerman L","year":"2021","unstructured":"Zimmerman L, McKeon B. Osteomalacia. In StatPearls [Internet]. StatPearls, Treasure Island, FL; 2021."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1586\/eem.09.27","article-title":"Tumor-induced osteomalacia","volume":"4","author":"Farrow EG","year":"2009","unstructured":"Farrow EG, White KE. Tumor-induced osteomalacia. Expert Rev Endocrinol Metab. 2009, 4:435-442. 10.1586\/eem.09.27","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa964","article-title":"Paraneoplastic secretion of multiple phosphatonins from a deep fibrous histiocytoma causing oncogenic osteomalacia","volume":"106","author":"Leow MKS","year":"2021","unstructured":"Leow MKS, Dogra S, Ge X, Chuah KL, Liew H, Loke KSH, McFarlane C. Paraneoplastic secretion of multiple phosphatonins from a deep fibrous histiocytoma causing oncogenic osteomalacia. J Clin Endocrinol Metab. 2021, 106:e2299-e2308. 10.1210\/clinem\/dgaa964","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00267","article-title":"Physiological actions of fibroblast growth factor-23","volume":"9","author":"Erben RG","year":"2018","unstructured":"Erben RG. Physiological actions of fibroblast growth factor-23. Front Endocrinol (Lausanne). 2018, 9:267. 10.3389\/fendo.2018.00267","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref6","article-title":"Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years","volume":"16","author":"McCANCE RA","year":"1947","unstructured":"McCANCE RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947, 16:33-46.","journal-title":"Q J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2017.09.002","article-title":"Tumor-induced osteomalacia","volume":"7","author":"Florenzano P","year":"2017","unstructured":"Florenzano P, Gafni RI, Collins MT. Tumor-induced osteomalacia. Bone Rep. 2017, 7:90-97. 10.1016\/j.bonr.2017.09.002","journal-title":"Bone Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.afos.2018.12.001","article-title":"Tumor-induced osteomalacia","volume":"4","author":"Yin Z","year":"2018","unstructured":"Yin Z, Du J, Yu F, Xia W. Tumor-induced osteomalacia. Osteoporos Sarcopenia. 2018, 4:119-127. 10.1016\/j.afos.2018.12.001","journal-title":"Osteoporos Sarcopenia"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016296","article-title":"Successful treatment of tumor-induced osteomalacia causing by phosphaturic mesenchymal tumor of the foot","volume":"98","author":"Liu S","year":"2019","unstructured":"Liu S, Zhou X, Song A, Huo Z, Wang Y, Xia W, Liu Y. Successful treatment of tumor-induced osteomalacia causing by phosphaturic mesenchymal tumor of the foot. Medicine (Baltimore). 2019, 98:e16296. 10.1097\/MD.0000000000016296","journal-title":"Medicine (Baltimore)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.10.1260","article-title":"Tumor-induced osteomalacia","volume":"294","author":"Jan de Beur SM","year":"2005","unstructured":"Jan de Beur SM. Tumor-induced osteomalacia. JAMA. 2005, 294:1260-1267. 10.1001\/jama.294.10.1260","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-017-1756-1","article-title":"Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients","volume":"18","author":"Zuo QY","year":"2017","unstructured":"Zuo QY, Wang H, Li W, et al.. Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients. BMC Musculoskelet Disord. 2017, 18:403. 10.1186\/s12891-017-1756-1","journal-title":"BMC Musculoskelet Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-015-0496-3","article-title":"Surgical treatment of tumor-induced osteomalacia: a retrospective review of 40 cases with extremity tumors","volume":"16","author":"Sun ZJ","year":"2015","unstructured":"Sun ZJ, Jin J, Qiu GX, Gao P, Liu Y. Surgical treatment of tumor-induced osteomalacia: a retrospective review of 40 cases with extremity tumors. BMC Musculoskelet Disord. 2015, 16:43. 10.1186\/s12891-015-0496-3","journal-title":"BMC Musculoskelet Disord"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"Jan de Beur SM","year":"2021","unstructured":"Jan de Beur SM, Miller PD, Weber TJ, et al.. Burosumab for the treatment of tumor-induced osteomalacia. J Bone Miner Res. 2021, 36:627-635. 10.1002\/jbmr.4233","journal-title":"J Bone Miner Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00351","article-title":"FGF23 in cardiovascular disease: innocent bystander or active mediator?","volume":"9","author":"St\u00f6hr R","year":"2018","unstructured":"St\u00f6hr R, Schuh A, Heine GH, Brandenburg V. FGF23 in cardiovascular disease: innocent bystander or active mediator?. Front Endocrinol (Lausanne). 2018, 9:351. 10.3389\/fendo.2018.00351","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013050465","article-title":"Fibroblast growth factor-23 and cardiovascular events in CKD","volume":"25","author":"Scialla JJ","year":"2014","unstructured":"Scialla JJ, Xie H, Rahman M, et al.. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol. 2014, 25:349-360. 10.1681\/ASN.2013050465","journal-title":"J Am Soc Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.000936","article-title":"Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study","volume":"3","author":"Lutsey PL","year":"2014","unstructured":"Lutsey PL, Alonso A, Selvin E, et al.. Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study. J Am Heart Assoc. 2014, 3:e000936. 10.1161\/JAHA.114.000936","journal-title":"J Am Heart Assoc"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-10-201005180-00004","article-title":"The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study","volume":"152","author":"Parker BD","year":"2010","unstructured":"Parker BD, Schurgers LJ, Brandenburg VM, et al.. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010, 152:640-648. 10.7326\/0003-4819-152-10-201005180-00004","journal-title":"Ann Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017121334","article-title":"Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: a meta-analysis","volume":"29","author":"Marthi A","year":"2018","unstructured":"Marthi A, Donovan K, Haynes R, et al.. Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: a meta-analysis. J Am Soc Nephrol. 2018, 29:2015-2027. 10.1681\/ASN.2017121334","journal-title":"J Am Soc Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.03.040","article-title":"Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study)","volume":"60","author":"Ix JH","year":"2012","unstructured":"Ix JH, Katz R, Kestenbaum BR, et al.. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol. 2012, 60:200-207. 10.1016\/j.jacc.2012.03.040","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.12.1340","article-title":"Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality","volume":"168","author":"Dobnig H","year":"2008","unstructured":"Dobnig H, Pilz S, Scharnagl H, et al.. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008, 168:1340-1349. 10.1001\/archinte.168.12.1340","journal-title":"Arch Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/60697-renal-phosphate-wasting-due-to-tumor-induced-oncogenic-osteomalacia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:34:24Z","timestamp":1707507264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/60697-renal-phosphate-wasting-due-to-tumor-induced-oncogenic-osteomalacia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.15507","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,7]]}}}